ID: MRFR/MED/2100-HCR | February 2021 | Region: Global | 85 pages
Market Synopsis of Global Carcinoid Syndrome Management:
Carcinoid syndrome comprises of signs and symptoms including flushing of the face, debilitating diarrhea, asthma caused due to vasoconstriction, intestinal bleeding, fast heartbeat, shortness of breath, sweating, unexplained weight gain etc. which are settled secondary to carcinoid tumor. The management or treatment of carcinoid syndrome often requires palliative and supportive care. Management of carcinoid syndrome involves drug therapy or surgical removal of carcinoid tumor from the organ.
Increasing incidence of hormonal disorders, growing smoking habits, levels of carcinogen in highly developed countries etc. are the major driving factor, driving the growth of the market. The only factor restraining the growth of global carcinoid syndrome management market is that no availability of drugs approved to manage carcinoid syndrome.
Figure 1 Global Carcinoid Syndrome Management Market by Organs Affected
Key players of Global Carcinoid Syndrome Management Market:
Key players profiled in the report are Novartis International AG (Sandoz) (Switzerland), Pharmascience Inc. (Canada), Omega Laboratories Ltd. (Canada), Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (USA), Ipsen Biopharmaceuticals, Inc.(US), Sirtex Medical Limited (Australia) , BTG International Ltd. (UK), Wockhardt Ltd. , and Sun Pharmaceutical Industries Limited (India),
The global carcinoid syndrome management market is segmented on the basis of organs affected by the disease, treatment procedures and end users. Based on organs affected by the disease, the market has been segmented into small intestine, lungs, rectum, appendix, colon, stomach, pancreas, liver and others. Based on treatment type, the market has been segmented into chemotherapy, biological therapy, and hepatic artery embolization agents. Further on the basis of end users the market has been segmented as hospital, clinics, and cancer institute and treatment centers.
The report for global Carcinoid Syndrome Management by Market Research Future comprises of extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
Frequently Asked Questions (FAQ) :
Rise in smoking among the populace, rising cases of hormonal disorders, and high levels of carcinogens among the people in developed countries are major factors driving the global carcinoid syndrome management market.
Low availability of drugs to manage the disease is the major restraining factor of the global carcinoid syndrome management market.
The Americas can dominate in the global carcinoid syndrome management market till 2023.
Pharmascience Inc., Novartis International AG, Mylan N.V., Ipsen Biopharmaceuticals, Inc., Wockhardt Ltd., Teva Pharmaceutical Industries Ltd., BTG International Ltd., Sun Pharmaceutical Industries Limited, Sirtex Medical Limited, and Omega Laboratories Ltd. are major players of the global carcinoid management market.
Acquisitions seem to be the major strategy of players in the global carcinoid syndrome management market.
Table of Contents
1.2 SCOPE OF STUDY
1.2.1 RESEARCH OBJECTIVE
1.2.2 ASSUMPTIONS & LIMITATIONS
1.3 MARKET STRUCTURE:
2 RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS:
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH:
3 MARKET DYNAMICS
3.4 MACROECONOMIC INDICATORS
4 MARKET FACTOR ANALYSIS
4.1 PORTERS FIVE FORCES MODEL
4.2 BARGAINING POWER OF SUPPLIERS
4.3 BARGAINING POWER OF BUYERS
4.4 THREAT OF NEW ENTRANTS
4.5 THREAT OF SUBSTITUTES
4.6 INTENSITY OF RIVALRY
5 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY ORGANS AFFECTED
5.1 SMALL INTESTINE
6. GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY TREATMENT TYPE
6.3 BIOLOGICAL THERAPY
6.4 HEPATIC ARTERY EMBOLIZATION AGENT
7. GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY END USERS
7.3 CENCER INSTITUTIONS AND TREATMENT CENTERS
8. GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY REGION
8.1 NORTH AMERICA
8.4 MIDDLE EAST & AFRICA
9. COMPETITIVE LANDSCAPE
9.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
9..1.1 STRATEGIC PARTNERSHIP
10..1.2 MERGER & ACQUISITION
10 COMPANY PROFILE
10.1 BTG INTERNATIONAL LTD.
10.1.2 PRODUCT OVERVIEW
10.1.4 KEY DEVELOPMENTS
10.2 IPSEN BIOPHARMACEUTICALS, INC.,
10.2.2 PRODUCT OVERVIEW
10.2.4 KEY DEVELOPMENTS
10.3 NOVARTIS INTERNATIONAL AG (SANDOZ)
10.3.2 PRODUCT OVERVIEW
10.3.5 KEY DEVELOPMENT
10.4 PHARMASCIENCE INC.,
10.4.2 PRODUCT OVERVIEW
10.4.4 KEY DEVELOPMENTS
10.5 TEVA PHARMACEUTICAL INDUSTRIES LTD.
10.5.2 PRODUCT OVERVIEW
10.5.4 KEY DEVELOPMENTS
List of Tables
TABLE 1 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY ORGANS AFFECTED, 2020-2027 (USD MILLION)
TABLE 2 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
TABLE 3 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKETBY END USERS 2020-2027 (USD MILLION)
TABLE 4 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY REGION 2020-2027 (USD MILLION)
List of Figures
FIGURE 1 RESEARCH PROCESS
FIGURE 2 PORTERS FIVE FORCES MODEL
FIGURE 3 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY ORGANS AFFECTED
FIGURE 4 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY TREATMENT TYPE
FIGURE 5 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY END USERS
FIGURE 6 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET, BY REGION
FIGURE 7 GLOBAL CARCINOID SYNDROME MANAGEMENT MARKET: COMPANY SHARE ANALYSIS, 2020 (%)